Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download New Horizons In Tumor Microenvironment Biology And Therapy Implications For New Therapies Vol Ii PDF full book. Access full book title New Horizons In Tumor Microenvironment Biology And Therapy Implications For New Therapies Vol Ii.
| Author | : Andreas Pircher |
| Publisher | : Frontiers Media SA |
| Total Pages | : 254 |
| Release | : 2022-08-19 |
| Genre | : Medical |
| ISBN | : 2889768295 |
| Author | : Yu Sun |
| Publisher | : LAP Lambert Academic Publishing |
| Total Pages | : 68 |
| Release | : 2015-03-30 |
| Genre | : |
| ISBN | : 9783659688218 |
The tumor microenvironment (TME) is being increasingly recognized as a key factor in multiple stages of disease progression, particularly local resistance, immune-escaping, and distant metastasis, thereby substantially impacting the future development of therapeutic interventions in clinical oncology. An appropriate understanding of the TME promotes evaluation and selection of candidate agents to control malignancies at both the primary sites as well as the metastatic settings. This book presents a timely outline of research advances in TME biology and highlights the prospect of targeting the TME as a critical strategy to overcome acquired resistance, prevent metastasis, and improve therapeutic efficacy. A body of frontline information is delivered to summarize recently emerging and rapidly progressing aspects of TME studies, and to provide a significant guideline for prospective development of personalized medicine, with the long term aim of providing a cure for cancer patients. The book is to shed new lights on the blooming fields of TME studies, should be especially useful to biomedical scientists and oncological clinicians, and people who care about personalized medicine.
| Author | : Peter P. Lee |
| Publisher | : Springer Nature |
| Total Pages | : 326 |
| Release | : 2020-03-25 |
| Genre | : Medical |
| ISBN | : 303038862X |
This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.
| Author | : Surajit Pathak |
| Publisher | : Springer Nature |
| Total Pages | : 369 |
| Release | : 2020-10-17 |
| Genre | : Medical |
| ISBN | : 9811551200 |
This book discusses the recent developments in the therapeutic implications of cancer stem cells for the effective diagnosis, prognosis, and treatment of cancer. It summarizes the various stem cells of common cancers including colon, pancreas, lungs, prostate, melanoma, and glioblastoma, and reviews the potential role of cancer stem cells in tissue aggressiveness, examining the functional contribution of cancer stem cells in the establishment and recurrence of cancerous tumors. Further, it explores the potential of cancer stem cells as novel therapeutic targets for the treatment and prevention of tumor progression. The book also discusses the various approaches for detecting, isolating, and characterizing different cancer stem cells and signaling pathways that control their replication, survival, and differentiation. Lastly, it explores the key features and mechanisms of drug resistance, chemo-resistance, and radio-resistance in cancer stem cells to improve therapeutic rationale.
| Author | : Gianfranco Baronzio |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 247 |
| Release | : 2009-04-10 |
| Genre | : Medical |
| ISBN | : 1402095767 |
In the post-genomic era, cancer is a genetic disease. However, cancer genotype does not always equal cancer phenotype. Cancers with the same genetic abnormalities don’t always behave the same. Understanding and eradicating cancers will require an appreciation for cancer’s ecology. This book is the first to comprehensively explore and critically appraise cancer microenvironments and host interactions with an eye towards exploiting our understanding for new treatments. The team of contributors share amongst them impressive experiences at the laboratory bench and in the clinic. These physician-scientists have dedicated themselves to the tension between the urgency for cures and the technical challenges of discovery. The target audience includes clinical oncologists, clinical hematologists, research oncologists, research hematologists, immunologists, stem cell researchers, oncology and hematology fellows (trainees), oncology educators (graduate and undergraduate levels), and course book for graduate students and undergraduate students.
| Author | : Peter P. Lee |
| Publisher | : |
| Total Pages | : |
| Release | : 2020 |
| Genre | : Cancer |
| ISBN | : 9783030388638 |
This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.
| Author | : Michael Molls |
| Publisher | : Springer |
| Total Pages | : 367 |
| Release | : 2010-11-16 |
| Genre | : Medical |
| ISBN | : 9783540868491 |
Te rapidly changing concepts in radiation oncology with the development of more precise - strumentation for delivery of radiation therapy and a greater emphasis on hypofractionation technologies require a very intimate knowledge of tumor biology and the infuence of various biologic factors on dose distribution within the tumor in terms of homogeneity as well as prev- tion of any late efects on normal tissue surrounding the tumor itself. Not only are these major factors in clinical practice but also the known factors of inhomogeneity of cancer cells, the impact of microenvironment in terms of radiation efect, and host factors make it mandatory to design therapeutic strategies to improve the outcome and to diminish any potential short-term or lo- term risks from the radiation therapy. Te authors have developed an outstanding text that deals with these strategies and how they would impact on established and emerging new technologies and treatment. Te context of the presentations within a multidisciplinary combined modality therapy program is incredibly - portant. In this volume, various topics are reviewed including tumor genesis, cell proliferation, - giogenesis, the physiologic characteristics of malignant tissues, invasion and adhesion, the route and role pursued in the development of metastasis, and the role of the human immune system in cancer prevention and development.
| Author | : Michael D. Waters |
| Publisher | : John Wiley & Sons |
| Total Pages | : 716 |
| Release | : 2017-11-10 |
| Genre | : Medical |
| ISBN | : 1119023629 |
Written by leading research scientists, this book integrates current knowledge of toxicology and human health through coverage of environmental toxicants, genetic / epigenetic mechanisms, and carcinogenicity. Provides information on lifestyle choices that can reduce cancer risk Offers a systematic approach to identify mutagenic, developmental and reproductive toxicants Helps readers develop new animal models and tests to assess toxic impacts of mutation and cancer on human health Explains specific cellular and molecular targets of known toxicants operating through genetic and epigenetic mechanisms
| Author | : Fumito Ito |
| Publisher | : Elsevier Health Sciences |
| Total Pages | : 400 |
| Release | : 2018-09-03 |
| Genre | : Medical |
| ISBN | : 0323549500 |
Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. Helps you translate current research and literature into practical information for daily practice. Presents information logically organized by disease site. Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. Consolidates today’s available information on this timely topic into one convenient resource.
| Author | : Charles Swanton |
| Publisher | : Perspectives Cshl |
| Total Pages | : 350 |
| Release | : 2017 |
| Genre | : Medical |
| ISBN | : 9781621821434 |
Tumor progression is driven by mutations that confer growth advantages to different subpopulations of cancer cells. As a tumor grows, these subpopulations expand, accumulate new mutations, and are subjected to selective pressures from the environment, including anticancer interventions. This process, termed clonal evolution, can lead to the emergence of therapy-resistant tumors and poses a major challenge for cancer eradication efforts. Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines cancer progression as an evolutionary process and explores how this way of looking at cancer may lead to more effective strategies for managing and treating it. The contributors review efforts to characterize the subclonal architecture and dynamics of tumors, understand the roles of chromosomal instability, driver mutations, and mutation order, and determine how cancer cells respond to selective pressures imposed by anticancer agents, immune cells, and other components of the tumor microenvironment. They compare cancer evolution to organismal evolution and describe how ecological theories and mathematical models are being used to understand the complex dynamics between a tumor and its microenvironment during cancer progression. The authors also discuss improved methods to monitor tumor evolution (e.g., liquid biopsies) and the development of more effective strategies for managing and treating cancers (e.g., immunotherapies). This volume will therefore serve as a vital reference for all cancer biologists as well as anyone seeking to improve clinical outcomes for patients with cancer.
